Jushi Holdings (JUSHF) Total Non-Current Liabilities (2021 - 2026)
Jushi Holdings' (JUSHF) quarterly Total Non-Current Liabilities came in at $494.8 million in Q1 2026, up 12.74% year-on-year from $438.9 million in Q1 2025, and up 4.95% on a QoQ basis from $471.5 million in Q4 2025.
Jushi Holdings (JUSHF) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has 6 years of Total Non-Current Liabilities data on file, last reported at $494.8 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 12.74% year-over-year to $494.8 million in Q1 2026; TTM through Mar 2026 was $494.8 million, a 12.74% increase from a year earlier, with the FY2025 full-year figure at $471.5 million, up 11.82% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $494.8 million, up from $471.5 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for JUSHF reached as high as $494.8 million in Q1 2026 and fell as low as $259.3 million in Q3 2022.
- Historically, Total Non-Current Liabilities has averaged $382.6 million across 5 years, with a median of $375.8 million in 2022.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 40.61% in 2023 and fell as far as 17.9% in 2023.
- Year by year, Total Non-Current Liabilities stood at $375.8 million in 2022, then slipped by 17.9% to $308.6 million in 2023, then soared by 36.66% to $421.7 million in 2024, then gained by 11.82% to $471.5 million in 2025, then climbed by 4.95% to $494.8 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $494.8 million in Q1 2026, $471.5 million in Q4 2025, and $424.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Jushi Holdings | 81.25 Mn | 41.54 Mn | 29.88 Mn | 494.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 494.85 Mn |
| Dec 31, 2025 | 471.50 Mn |
| Sep 30, 2025 | 423.98 Mn |
| Jun 30, 2025 | 447.08 Mn |
| Mar 31, 2025 | 438.92 Mn |
| Dec 31, 2024 | 421.66 Mn |
| Sep 30, 2024 | 411.23 Mn |
| Jun 30, 2024 | 405.29 Mn |
| Mar 31, 2024 | 317.14 Mn |
| Dec 31, 2023 | 308.55 Mn |
| Sep 30, 2023 | 364.58 Mn |
| Jun 30, 2023 | 346.39 Mn |
| Mar 31, 2023 | 368.98 Mn |
| Dec 31, 2022 | 375.82 Mn |
| Sep 30, 2022 | 259.28 Mn |
| Jun 30, 2022 | 330.09 Mn |
| Mar 31, 2022 | 318.06 Mn |
| Dec 31, 2021 | 387.14 Mn |